Prodotti competitors / Area HIV 14 febbraio 2025 APRETUDE Reimbursement Milestones in Scotland and Canada
Prodotti competitors / Area HIV 3 febbraio 2025 European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
Prodotti competitors / Area HIV 10 dicembre 2024 Apretude: PRAC reviewed with inclusion of new adverse events/warning in the SmPC
Prodotti competitors / Area HIV 21 ottobre 2024 ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024 Download (PDF, 271.8KB)
Prodotti competitors 11 ottobre 2024 Lancet: Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension
Prodotti competitors / Area HIV 9 ottobre 2024 ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
Autorità nazionali 13 settembre 2024 Esiti riunione Commissione Scientifica e Economica del Farmaco (CSE) 16-20 settembre 2024
Prodotti competitors / Area HIV 24 luglio 2024 ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024
Regulatory news / Area HIV 12 luglio 2024 WHO implementation tool for pre-exposure prophylaxis of HIV infection: provider module for oral and long-acting PrEP
